SAB Biotherapeutics Financials - Benzinga

SAB Biotherapeutics Inc

SABSNASDAQ

Trade with Public

Trade with Public

$3.93

0.051.29%

At close: Aug 27, 5:00 PM EST

$3.93

N/A

After Hours: 4:01 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

SAB Biotherapeutics Financials

SAB Biotherapeutics (SABS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
SAB Biotherapeutics Q2 2026, Cash Balance Of $208.0M, Providing Runway Through 2028

Benzinga Newsdesk

PRO
SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate.

SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. This is a 37.5 percent increase over losses of $(0.56) per share from

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
SAB Biotherapeutics Q2 EPS $(1.09) Misses $(0.49) Estimate

Benzinga Newsdesk

Gold Gains 1%; Boeing Shares Rise Following Q4 Results

Avi Kapoor

PRO
SAB BIO Q3 2024 Cash, Cash Equivalents Available $30.4M-$56.6M

Benzinga Newsdesk